Diazine-ethyenylphenyl oxamic acids and esters and salts thereof

ABSTRACT

Compounds of the formula ##STR1## R 1  is hydrogen or alkyl of 1 to 4 carbon atoms; R 2  is hydrogen, methyl, hydroxyl, alkoxy of 1 to 4 carbon atoms, di(alkyl of 1 to 2 carbon atoms)amino-(alkoxy of 1 to 4 carbon atoms) or NHCOCOOR 1  ; 
     R 3  is hydrogen or NHCOCOOR 1  ; 
     A is ##STR2## R 4  is hydrogen, methyl, alkoxy of 1 to 4 carbon atoms, hydroxyl, amino, alkanoyloxy of 1 to 2 carbon atoms, di(alkyl of 1 to 2 carbon atoms)-amino-(alkoxy of 1 to 4 carbon atoms) or acetamido; and 
     R 5  is hydrogen, amino, alkoxy of 1 to 4 carbon atoms, halogen or NHCOCOOR 1  ; 
     and, when R 1  is hydrogen, nontoxic, pharmaceutically acceptable salts thereof. The compounds as well as their salts are useful for the treatment of immunological, inflammatory and allergic disorders such as asthma, rhinitis, conjunctivitis, hay fever, urticaria, food allergies and the like.

This is a division of U.S. Ser. No. 733,007, filed on May 10, 1985, nowU.S. Pat. No. 4,681,884, which is a continuation-in-part of U.S. Ser.No. 528,522, filed on Sept. 1, 1983, now abandoned.

This invention relates to novel diazine-ethenylphenyl oxamic acids andesters and salts thereof, to methods of preparing these compounds, topharmaceutical compositions containing them as active ingredients, andto methods of using them for the treatment of immunological,inflammatory and allergic disorders.

THE PRIOR ART

Cromoglycate, normally administered as the sodium salt, is a potent anduseful antiallergic, commonly prescribed for the treatment of bronchialasthma. Cromoglycate has for many years been accepted as an effectivebronchodilator when given by inhalation as a solid. However, it is knownto have certain disadvantages; for instance, it is not active when givenorally, which warrants a search for new orally active antiallergics.

A number of oxamate derivatives have been disclosed in the patent andscientific literature. Illustrative of such prior art are the following:

(a) 4-Substituted thiazol-2-oxamic acids, U.S. Pat. No. 4,238,496 and

(b) N,N'-(Phenylene)dioxamic acid and its derivatives, GermanOffenlegungsschrift No. 2,362,409.

The prior art, however, does not disclose diazine-ethenylphenyl oxamicacids or their esters or salts.

SUMMARY OF THE INVENTION

The present invention relates to novel diazine-ethenylphenyl oxamicacids and esters of formula I ##STR3## wherein

R₁ is hydrogen or alkyl of 1 to 4 carbon atoms;

R₂ is hydrogen, methyl, hydroxyl, alkoxy of 1 to 4 carbon atoms,di(alkyl of 1 to 2 carbon atoms)amino(alkoxy of 1 to 4 carbon atoms) orhalogen;

R₃ is hydrogen or NHCOCOOR₁ ;

A is ##STR4##

R₄ is hydrogen, halogen, methyl, alkoxy of 1 to 4 carbon atoms,hydroxyl, amino, alkanoyloxy of 1 to 2 carbon atoms, di(alkyl of 1 to 2carbon atoms)-amino-(alkoxy of 1 to 4 carbon atoms or acetamido; and

R₅ is hydrogen, amino, alkoxy of 1 to 4 carbon atoms, or NHCOCOOR₁ ;

and, when R₁ is hydrogen, nontoxic, pharmaceutically acceptable saltsthereof, especially their alkali metal and primary or secondary aminesalts.

In subgeneric aspects, the invention comprehends compounds of formula Iwherein

R₁ is hydrogen or ethyl,

R₂ is hydrogen,

R₃ is --NHCOCOOR₁

A is ##STR5##

R₄ is hydrogen or methyl, and nontoxic, pharmaceutically acceptablesalts thereof.

The compounds of the present invention, that is, those embraced byformula I above and their nontoxic, pharmaceutically acceptable salts,exhibit immunological, anti-inflammatory and anti-allergic activities inwarm-blooded animals such as rats. They are useful for the treatment ofmammals suffering allergic or inflammatory disorders such as asthma,rhinitis, conjunctivitis, hay fever, urticaria, food allergies and thelike.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Although specific terms are used in the following description forclarity, they refer only to the particular embodiment(s) selected forillustration, and are not intended to limit the scope of the invention.

The compounds of the present invention can be prepared by severalmethods, selected ones of which are described below. The startingmaterials used in the examples are commercially available or can besynthesized by well known published procedures from commerciallyavailable materials unless otherwise fully described here. Standardreagent grade chemicals are used in these preparations and in theworking examples which follow unless otherwise specifically indicated.

The compounds embraced by Formula I can be prepared from a[2-(aminophenyl)ethyl]diazine (II) ##STR6## wherein A, R₂ and R₃ havethe same meanings as in Formula I by treating it with an oxalate halide,preferably the chloride, or with a dialkyl oxalate, optionally followedby hydrolysis of the ester group.

The reaction is carried out by dissolving or suspending the[2-(aminophenyl)ethenyl]diazine starting material (II) or an acidaddition salt thereof, in an inert liquid medium, and admixing theoxalic acid derivative, e.g. the oxalate halide or dialkyl oxalate,dropwise with the solution or suspension. Examples of suitable inertliquid media are benzene, toluene, xylene, methylene chloride,dimethylformamide or tetrahydrofuran. In addition, it is preferred toadd an organic base, such as pyridine or triethylamine, to the reactionmixture to neutralize the acid released by the reaction. Since thereaction is strongly exothermic, the oxalic acid derivative should beadded slowly and, if necessary, while cooling.

Since most [2-(aminophenyl)ethenyl]diazines (II) are sparsely soluble,it is of advantage to let the reaction mixture stand for an extendedperiod of time, for instance overnight, with or without stirring, beforeisolating the reaction product.

The reaction mixture is then processed in conventional manner, that is,by evaporating the inert liquid medium, extracting the residue with asuitable solvent or solvent mixture, such as ether, ethyl acetate,chloroform, hexane or mixtures of any two or more of these, purifyingthe extract solution, evaporating the solvent, and recrystallizing theresidue. In some cases further purification by column chromatography isof advantage.

If it is desired to obtain an end product of the Formula I wherein R₁ ishydrogen, the ester group is removed by hydrolysis with a basic or acidcatalyst. Suitable such catalysts are strong bases such as sodiumhydroxide or potassium hydroxide, or mineral acids such as hydrochloricacid, sulfuric acid or phosphoric acid.

The [2-(aminophenyl)ethenyl]diazines (II) are prepared by a processwhich comprises

(a) Reaction of a nitrobenzaldehyde (III) with a methyldiazine[pyrimidine (IVA), pyrazine (IVB) or pyridazine (IVC)]in a suitablesolvent such as acetic anhydride, formic acid or the like to produce acorresponding [2-(nitrophenyl)ethenyl]diazine (VA, VB or VC) pursuant tothe following reaction scheme: ##STR7##

(b) and, thereafter, reduction of the [2-(nitrophenyl)ethenyl]diazine(VA, VB or VC) to the corresponding amine (i) with a metal or metalsalt, such as iron, tin or zinc, in an aqueous acid according to A. J.Bechamp, Ann. Chim. Phys. [3] 42, 186, (1854), or (ii) catalyticallywith hydrogen using Raney Nickel as a catalyst in a suitable solventsuch as ethanol or tetrahydrofuran; or with hydrazine in the presence ofa catalyst, such as palladium.

The preparation of some [2-(nitrophenyl)ethenyl]-diazine derivatives isdescribed in the literature. For example,4-[2-(p-nitrophenyl)ethenyl]2-aminopyrimidine ##STR8## can be preparedaccording to the procedure disclosed in Chemical Abstracts 62: 19448c(Japanese Pat. No. 19652, 1964). Similarly, the compounds ##STR9## canbe prepared by the general procedures described in J. Med. Chem. 1290(1970), J. Chem. Soc. C 1343 (1967) and J. Pharm. Soc. Jap. 72, 909(1953).

The following examples illustrate the present invention and enableothers skilled in the art to understand it more completely. However, theinvention is not limited solely to the particular examples given below.

EXAMPLE 1 Ethyl 2-(4-pyrimidinyl)ethenylphenyl-4 oxamate

Ethyl oxalyl chloride (1.2 g) is added dropwise to a suspension of4-[2-(p-aminophenyl)ethenyl]-pyrimidine (1.3 g) in methylene chloride(30 ml) containing pyridine (1.6 ml), and the mixture is stirredovernight at room temperature. Thereafter, the reaction mixture iswashed first with an aqueous sodium bicarbonate solution, then withwater and then with a saturated aqueous sodium chloride solution, driedover magnesium sulfate and finally evaporated to dryness. The residue isrecrystallized from chloroform and petroleum ether, and gives ethyl2-(4-pyrimidinyl)ethenylphenyl-4 oxamate (1.3 g), which has a meltingpoint of 171°-173° C.

The starting compound is prepared as follows. p-Nitrobenzaldehyde (24.2g), 4-methyl-pyrimidine (15.5 g) and acetic anhydride (16.7 g) are mixedat room temperature, and the mixture is heated at 120° C. for 5 hours.After cooling, the mixture is poured into water (500 ml), and theaqueous mixture is extracted several times with chloroform. The combinedchloroform extracts are dried over magnesium sulfate and concentrateduntil crystals separated. Addition of ether gives4-[2-(p-nitrophenyl)ethenyl]pyrimidine (28 g), m.p. 213°-215° C.

Hydrochloric acid (100 ml of 4N) is added dropwise to a mixture of4-[2-(p-nitrophenyl)ethenyl]pyrimidine (28 g), ethanol (250 ml) and ironfilings (28 g). The reaction temperature is increased to 65° C., and themixture is stirred at that temperature for two hours. Water is added,followed by an aqueous 30% potassium hydroxide solution (200 ml), andchloroform (1 liter). The mixture is filtered through celite, and thechloroform layer is separated, dried over sodium sulfate and thenconcentrated. Addition of ether gives4-[2-(p-aminophenyl)ethenyl]pyrimidine (10.3 g), m.p. 227°-230° C.,which is used as the starting compound without further purification.

EXAMPLE 2 2-(4-Pyrimidinyl)ethenylphenyl-4 oxamic acid and itsethanolamine salt

Sodium hydroxide solution (13.5 ml of a 1N) is added dropwise to asuspension of ethyl 4-[2-(4-pyrimidinyl)ethenyl]phenyl oxamate (4 g)(see Example 1) in water (50 ml) and ethanol (50 ml) while vigorouslystirring until a clear solution is formed. The resulting solution isacidified with 2N hydrochloric acid, and the precipitate formed therebyis filtered off. The filter cake is dried to give2-(4-pyrimidinyl)ethenylphenyl-4 oxamic acid (2 g), m.p. 214°-216° C.

The acid is suspended in a mixture of N,N-dimethyl formamide (50 ml),and ethanolamine (1 g), and the precipitate formed thereby is filteredoff and washed with ether. The ethanolamine salt (1.3 g) of the acidcompound, m.p. 202°-205° C., is obtained.

EXAMPLE 3 Ethyl 2-(2-ethoxyoxalylaminopyrimidin-4-yl)-ethenylphenyl-4oxamate

Ethyl oxalyl chloride (19 ml) is added dropwise to a solution of4-[2-(p-aminophenyl)ethenyl]-2-aminopyrimidine (13.5 g) in dry pyridine(75 ml). The reaction mixture is then stirred (12 hours) at roomtemperature. The progress of the reaction is periodically checked bythin-layer chromatography. After the completion of the reaction, thereaction mixture is poured into ice water. The crude product isextracted with chloroform, dried and purified on a silica gel column.After recrystallization from chloroform and ether, ethyl2-[2-(ethoxyoxalylaminopyrimidin-4-yl)ethenyl]phenyl-4 oxamate (9.0 g),m.p. 191°-193° C., is obtained.

The starting compound is prepared as follows. A solution of2-amino-4-methylpyrimidine (21.8 g) and p-nitrobenzaldehyde (30.2 g) informic acid (45 ml) is refluxed (24 hours). After cooling, the reactionmixture is poured into water (1 liter), and the aqueous mixture isneutralized with a 5N sodium hydroxide solution. The crude product isextracted with chloroform, and the extract is dried over sodium sulfateand concentrated to dryness. The crude product is purified on a silicagel column to give 4-[2-(p-nitrophenyl)ethyenyl]-2-aminopyrimidine (27.8g), m.p. 214°-216° C., which is used for the next step withoutpurification.

Hydrochloric acid (100 ml of 4N) is added dropwise to a stirred mixtureof 4-[2-(p-nitrophenyl)-ethenyl]-2-aminopyrimidine (21.8 g), ethanol(250 ml) and iron filing (22 g). During the addition the reactiontemperature is increased to 65° C., and stirring is continued (2 hours)at 65° C. Water is added, followed by an aqueous 30% sodium hydroxidesolution (200 ml) and chloroform (1 liter). The chloroform layer is thenseparated and dried over sodium sulfate. After evaporation and additionof ether, 4-[2-(p-aminophenyl)-ethenyl]-2-aminopyrimidine is obtained(13.5 g), which is used as the starting compound without furtherpurification.

Using the appropriate starting compounds and the procedures described inthe preceding examples the following compounds of the formula ##STR10##where also prepared:

      Example       No. Nomenclature A R.sub.2 R.sub.3 NHCOCOOR.sub.1 m.p.     °C.              4 Ethyl 2-(4-pyrimidinyl)ethenylphenyl-3 oxamate      ##STR11##      H H 3-NHCOCOOC.sub.2 H.sub.5 127-128                                    o      5 2-(4-Pyrimidinyl)ethenylphenyl-3xamic acid ethanolamine salt      ##STR12##      H H 3-NHCOCOOHEthanolaminesalt 161-163                                  p      6 Ethyl 2-(4-pyrimidinyl)ethenylhenyl-2 oxamate      ##STR13##      H H 2-NHCOCOOC.sub.2 H.sub.5 105-110                                    o      7 2-(4-Pyrimidinyl)ethenylphenyl-2xamic acid ethanolamine salt      ##STR14##      H H 2-NHCOCOOHEthanolaminesalt 151-153      8 Ethyl 2-(4-pyrimidinyl)ethenyl-2-hydroxphenyl-4 oxamate      ##STR15##      2-OH H 4-NHCOCOOC.sub.2 H.sub. 5 145-147      9 Ethyl 2-(4-pyrimidinyl)ethenyl-6-chlorophenyl-3 oxamate      ##STR16##      6-Cl H 3-NHCOCOOC.sub.2 H.sub.5 147-148      10 Ethyl 2-(4-pyrimidinyl)ethenyl-3-N,Ndimethylamino-ethoxyphenyl-4oxama     te      ##STR17##      3-OCH.sub.2 CH.sub.2N(CH.sub.3).sub.2 H 4-NHCOCOOC.sub.2 H.sub.5     156-159      11 Ethyl 2-(4-pyrimidinyl)ethenyl-4-oxamate     ##STR18##      4-OCH.sub.2 CH.sub.2N(CH.sub.3).sub.2 H 3-NHCOCOOC.sub.2      H.sub.5sesquihydro-chloride 176-178                                     p      12 Diethyl 2-(4-pyrimidinyl)ethenylhenyl-2,4 dioxamate      ##STR19##      2-NHCOCOOC.sub.2 H.sub.5 H 4-NHCOCOOC.sub.2 H.sub.5 135-137  13 Ethyl     2-(2,6-diethoxypyrimidin-4-yl)ethenylphenyl-4 oxamate      ##STR20##      H H 4-NHCOCOOC.sub.2 H.sub.5 156-159      14  Ethyl 2-(2-methyl-6-aminopyrimidin-4-yl)ethenylphenyl-4 oxamate      ##STR21##      H H 4-NHCOCOOC.sub.2 H.sub.5 267-269      15 Ethyl 2-(6-methylpyrimidin-4-yl)ethenylphenyl-4 oxamate      ##STR22##      H H 4-NHCOCOOC.sub.2 H.sub.5 149-151      16 Ethyl 2-(2-acetamidopyrimidin-4-yl)ethenylphenyl-3 oxamate      ##STR23##      H H 3-NHCOCOOC.sub.2 H.sub.5 234-236      17 2-(2-Acetamidopyrimidin-4-yl)ethenylphenyl-3 oxamic acidtromethane     salt      ##STR24##      H H 3-NHCOCOOHTromethane salt 195-197                                   p      18 Ethyl 2-(3-pyridazinyl)ethenylhenyl-4 oxamate      ##STR25##      H H 4-NHCOCOOC.sub.2 H.sub.5 203-205      19 2-(3-Pyridazinyl)ethenylphenyl-4oxamic acid ethanolamine salt      ##STR26##      H H 4-NHCOCOOHEthanolamine salt 199-201                                 p      20 Ethyl 2-(2-pyrazinyl)ethenylhenyl-4-oxamate      ##STR27##      H H 4-NHCOCOOC.sub.2 H.sub.5 165-166      21 2-(2-Pyrazinyl)ethenylphenyl-4oxamic acid sodium salt      ##STR28##      H H 4-NHCOCOOHSodium salt >300  22 Ethyl 2-(2-pyrazinyl)ethenylphenyl-3     oxamate      ##STR29##      H H 3-NHCOCOOC.sub.2 H.sub.5 131-133      23 2-(2-Pyrazinyl)ethenylphenyl-3oxamic acid ethanolamine salt      ##STR30##      H H 3-NHCOCOOHEthanolamine salt 205-208      24 Ethyl 2-(2-methyl-6-ethoxyoxalyl-aminopyrimidin-4-yl)-ethenylphenyl-4      oxamate      ##STR31##      H H 4-NHCOCOOC.sub.2 H.sub.5 203- 205                                   a      25 2-(2-Methyl-6-carboxycarbonyl-minopyrimidin-4-yl)-ethenylphenyl-4-oxa     mic acid hydratediethanolamine salt      ##STR32##      H H 4-NHCOCOOHdiethanolaminehydrate salt 274-275      26 Ethyl 2-(2-methyl-6-ethoxyoxalyl-aminopyrimidin-4-yl)-ethenylphenyl-3      oxamate hemihydrate      ##STR33##      H H 3-NHCOCOOC.sub.2 H.sub.5hemihydrate 197-199      27 2-(2-Methyl-6-carboxycarbonyl-aminopyrimidin-4-yl)-ethenylphenyl-3-ox     amic acid di-tromethane salt      ##STR34##      H H 3-NHCOCOOHdi-tromethanesalt 197-199                                 p      28 Ethyl 2-(2-ethoxyoxalylaminoyrimidin-4-yl)-ethenylphenyl-3oxamate      ##STR35##      H H 3-NHCOCOOC.sub.2 H.sub.5 199-201      29 2(2-Carboxycarbonylamino-pyrimidin-4-yl)ethenyl-phenyl-3 oxamic acid     tetra-sodium saltdihydrate      ##STR36##      H H 3-.sup.⊖NCOCOO.sup.⊖tetra-sodiumsalt dihydrate >350      30 Ethyl 2-(3-ethylpyrazin-2-yl)ethenylphenyl-4 oxamate     ##STR37##      H H 4-NHCOCOOC.sub.2 H.sub.5 143-145      31 2-(3-Ethylpyrazin-2-yl)ethenylphenyl-4 oxamic acid ethanolaminesalt      ##STR38##      H H 4-NHCOCOOHEthanolaminesalt 173-175      32 Ethoxyethyl 2-(2-pyrazinyl)ethenylphenyl-4 oxamate      ##STR39##      H H 4-NHCOCOOCH.sub.2CH.sub.2 OC.sub.2 H.sub.5 122-124  33 Ethoxyethyl     2-(2-methyl-6-amino-pyrimidin4-yl)-ethenylphenyl-4oxamate hemihydrate      ##STR40##      H H 4-NHCOCOOCH.sub.2CH.sub. 2 OC.sub.2 H.sub.5hemihydrate 201-202   34 D     iethyl 2-(2-pyrazinyl)ethenylphenyl-2,4-dioxamate      ##STR41##      H 2-NHCOCOOC.sub.2 H.sub.5 4-NHCOCOOC.sub.2 H.sub.5 172-174  35     2-(2-Pyrazinyl)ethenylphenyl-2,4 dioxamic acid diethanolaminesalt      ##STR42##      H 2-NHCOCOOHdi-ethanol-amine salt 4-NHCOCOOH 193-196      36 2-(4-Pyrimidinyl)ethenylphenyl-2,4 dioxamic aciddiethanolamine salt      ##STR43##      H 2-NHCOCOOHdi-ethanol-amine salt 4-NHCOCOOH n.d.      37 Diethyl 2-(6-chloro pyridazin-3-yl)ethenyl (4-chlorophenyl)-3,5dioxam     ate      ##STR44##      4-Cl 3-NHCOCOOC.sub.2 H.sub.5 5-NHCOCOOC.sub.2 H.sub.5 220-22

EXAMPLE 38 Passive Cutaneous Anaphylaxis (PCA) Assay

Representative compounds of the present invention were testedcomparatively with cromoglycate to determine in vivo anti-allergicactivity. The anti-allergic properties were ascertained in rats by thePassive Cutaneous Anaphylaxis test (PCA) essentially as described byGoose and Blair, Immunology, 16: 749-760 (1969).

Rat serum was diluted so that skin reactions with diameters between 10and 15 mm in unsensitized rats were produced. The PCA test was performedin duplicate by injecting 0.1 ml of this antiserum dilution on each sideof the shaved back of rats. Rats so treated were injected intravenously(i.v.) twenty-four hours later with 0.02 mg ovalbumin in 0.5 ml of 1%Evans Blue solution within five minutes after intravenous administrationor 30 minutes after oral administration of the test compounds. Thirtyminutes after the ovalbumin challenge the rats were killed by CO₂-asphyxiation, and the skin was reflected. The diameters, inmillimeters, of the blued areas were measured and the mean diameter wasdetermined. The circular area was calculated, and the mean area insquare millimeters of the control group was considered as 100%. Theresults of the compound test groups were expressed as a percentagechange from these control values. From dose response curves the dosereducing the size of the blued area by 50% (ED₅₀) was estimated.

The following table shows the results of this test:

    __________________________________________________________________________    Compound of                                 % Inhibition                                                                             ED.sub.50              Example No.                                                                          Nomenclature                         (10 mg/kg, p.o.)                                                                         (mg/kg,                __________________________________________________________________________                                                           p.o.)                         Cromoglycate                         n.d.       Inactive                1     Ethyl 2-(4-pyrimidinyl)ethenylphenyl-4 oxamate                                                                     n.d.*      1.4                     2     2-(4-Pyrimidinyl)ethenylphenyl-4 oxamic acid ethanolamine                                                          63%t                                                                             (3 mg/kg,                                                                             n.d.*                   3     Ethyl 2-(2-ethoxyoxalylaminopyrimidin-4-yl) ethenylphenyl-4                   oxamate                              n.d.       10                      4     Ethyl 2-(4-pyrimidinyl)ethenylphenyl-3 oxamate                                                                     n.d.       2.8                     5     2-(4-Pyrimidinyl)ethenylphenyl-3 oxamic acid ethanolamine                                                          n.d.       12.3                    6     Ethyl 2-(4-pyrimidinyl)ethenylphenyl-2 oxamate                                                                     20%        n.d.                    7     2-(4-Pyrimidinyl)ethenylphenyl-2 oxamic acid ethanolamine                                                          n.d.        8                      8     Ethyl 2-(4-pyrimidinyl)ethenyl-2-hydroxphenyl-4 oxamate                                                            n.d.       4.5                     9     Ethyl 2-(4-pyrimidinyl)ethenyl-5-chlorophenyl-3 oxamate                                                            n.d.        2                     10     Ethyl 2-(4-pyrimidinyl)ethenyl-3-N,N--dimethylaminoethoxyphenyl-4             oxamate                              n.d.       n.d.                   11     Ethyl 2-(4-pyrimidinyl)ethenyl-4-N,N--dimethylaminoethoxyphenyl-3             oxamate                              9%         n.d.                   12     Diethyl 2-(4-pyrimidinyl)ethenylphenyl-2,4-dioxamate                                                               n.d.        2                     13     Ethyl 2-(2,6-diethoxypyrimidin-4-yl)ethenyl phenyl-4                                                               n.d.ate    30                     14     Ethyl 2-(2-methyl-6-aminopyrimidin-4-yl)ethenyl phenyl-4                                                           n.d.ate    10                     15     Ethyl 2-(6-methylpyrimidin-4-yl)ethenylphenyl-4 oxamate                                                            n.d.       1.1                    16     Ethyl 2-(2-acetamidopyrimidin-4-yl)ethenyl phenyl-3                                                                42%mate    n.d.                   17     2-(2-Acetamidopyrimidin-4-yl)ethenylphenyl-3 oxamic acid                      tromethane salt                      37%        n.d.                   18     Ethyl 2-(3-pyridazinyl)ethenylphenyl-4 oxamate                                                                     n.d.        1                     19     2-(3-Pyridazinyl)ethenylphenyl-4 oxamic acid ethanolamine                                                          0%lt       n.d.                   20     Ethyl 2-(2-pyrazinyl)ethenylphenyl-4 oxamate                                                                       n.d.       4.6                    21     2-(2-Pyrazinyl)ethenylphenyl-4 oxamic acid sodium                                                                  n.d.       10                     22     Ethyl 2-(2-pyrazinyl)ethenylphenyl-3 oxamate                                                                       n.d.        4                     23     2-(2-Pyrazinyl)ethenylphenyl-3 oxamic acid ethanolamine                                                            n.d.       <1                     24     Ethyl 2-(2-methyl-6-ethoxyoxalylaminopyrimidin-4-                                                                  n.d.       0.3                           yl)-ethenylphenyl-4 oxamate                                            25     2-(2-Methyl-6-carboxycarbonylaminopyrimidin-4-                                                                     n.d.       4.0                           yl)-ethenylphenyl-4 oxamic acid hydrate diethanolamine salt            26     Ethyl 2-(2-methyl-6-ethoxyoxalyl-aminopyrimidin-                                                                   64%        <10.0                         4-yl) ethenylphenyl-3 oxamate hemihydrate                              27     2-(2-Methyl-6-carboxycarbamyl-aminopyrimidin-4-                                                                    0%         0.03 mg/kg, i.v.              yl)ethenyl-3 oxamic acid di-tromethane salt                            28     Ethyl 2-(2-ethoxyoxalylamino-pyrimidin-4-yl) ethenyl-phenyl-3                 oxamate                              5%         n.d.                   29     2-(2-Carboxycarbonylamino-pyrimidin-4-yl)ethenyl-                                                                  67%                                                                              (repeat 2%)                                                                           n.d.                          phenyl-3 oxamic acid tetra-sodium salt di-hydrate                      30     Ethyl 2-(3-ethylpyrazin-2-yl)ethenylphenyl-4 oxamate                                                               6%         n.d.                   31     2-(3-Ethylpyrazin-2-yl)ethenyl-phenyl-4 oxamic acid ethanolamine              salt                                 15%        n.d.                   32     Ethoxyethyl 2-(2-pyrazinyl)ethenylphenyl-4 oxamate                                                                 46%        n.d.                   33     Ethoxyethyl 2-(2-methyl-6-aminopyrimidin-4-yl)-                                                                    52%        n.d.                          ethenylphenyl-4 oxamate hemihydrate                                    34     Diethyl 2-(2-pyrazinyl)ethenylphenyl-2,4-dioxamate                                                                 n.d.       n.d.                   35     2-(2-Pyrazinyl)ethenylphenyl-2,4 dioxamic acid di-ethanolamine                salt                                 n.d.       0.53 mg/kg, i.v.       36     2-(4-Pyrimidinyl)ethenylphenyl-2,4 dioxamic acid di-ethanolamine              salt                                 n.d.       0.05 mg/kg, i.v.       37     Diethyl 2-(6-chloro pyridazin-3-yl)ethenyl(4-chlorophenyl)-3.5                dioxamate                            54%        n.d.                   __________________________________________________________________________     *not determined                                                          

Pharmaceutical compositions containing the compounds according to theinvention can be administered to warm-blooded animals orally,intravenously, perorally, parenterally, rectally or by the respiratoryroute. Such compositions generally include an inert pharmaceuticalcarrier and a therapuetically effective amount of the active ingredient.

When the compounds of formula I are given by the oral route, they can beformulated in the form of syrups, tablets, capsules (for example ofgelatin), pills and the like. Preferably, the compositions are in unitdosage form, or in a form in which the patient can administer to himselfa single dose. When the composition is in the form of a tablet, powderor lozenge, any pharmacuetical carrier suitable for formulating solidcompositions may be used. Examples of such carriers are variousstarches, lactose, glucose, mannitol, sucrose, cellulose,methylcellulose, microcrystalline cellulose, talcum, pyrogenic silica,dicalcium phosphate, and high molecular weight polymers such aspolyethylene glycol. Suitable liquid pharmaceutical carriers includeglycerin, saline, water, propylene glycol or sorbitol solution, whichmay be compounded with flavoring or coloring agents to form syrups.

The compounds of this invention can also be prepared into compositionssuitable for administration by other than the oral route. Thecompositions can be formulated, for example, for rectal administrationas a suppository or for presentation in an injectable form in an aqueousor non-aqueous solution, suspension or emulsion in a pharmaceuticallyacceptable liquid, such as sterile, pyrogen-free water or a parenterallyacceptable oil or a mixture of liquids, which may contain bacteriostaticagents, antioxidants, preservatives, buffers, or other solutes to renderthe solution isotonic with the blood, thickening agents, suspendingagents or other pharmaceutically acceptable additives. Preservatives caninclude benzoic acid, methylene propylparaben, benzalkonium chloride orother quanternary ammonium compounds. Stabilizing agents, solubilizingagents and/or buffers conventionally used for injection solutionsinclude, for example, tartrate, citrate and acetate buffers, ethanol,propylene glycol, polyethylene glycol, complex formers (such as EDTA),antioxidants (such as sodium bisulfate, sodium metabisulfate or ascorbicacid), high-molecular-weight polymers (such as liquid-polyethyleneoxides) for viscosity regulation, and polyethylene derivatives ofsorbitol anhydrides. Such forms can be presented in unit dose forms suchas ampules or disposable injection devices or in multi-dose vials suchas a bottle from which a appropriate dose may be withdrawn, or in solidform or concentrate which can be used to prepare an injectableformulation.

Compounds of this invention can also be suitably presented foradministration to the respiratory tract as an aerosol or solution for anebulizer, or as a microfine powder for insufflation, alone or incombination with an inert carrier such as lactose. In such a case theparticles of active compounds suitably have diameters of less than 20microns, preferably less than 10 microns. Where appropriate, smallamounts of other anti-allergics, anti-asthmatics and bronchodilators,for example, sympathomimetic amines such as isoprenaline, isoetharine,metaproterenol, salbutamol, phenylephrine, fenoterol and ephedrine;xanthine derivatives such as theophylline and aminophylline;corticosteroids such as predenisolone and adrenal stimulants such asACTH may be included.

Compounds of this invention may also be presented as an ointment, cream,lotion, gel, aerosol or solution for topical application to the nose oreye or as any of these and powders as topical applications to the skin.

In any of the foregoing formulations, a suitable dosage unit may containfrom 1 to 500 mg of active ingredient. The effective dose of compoundsof this invention depends on the particular compound employed, thecondition of the patient and on the frequency and route ofadministration. In general it is orally administered in the range offrom about 0.1 mg/kg to at least about 10 mg/kg body weight.

The following examples illustrate pharmaceutical dosage unitcompositions comprising a compound of the present invention as an activeingredient and represent the best modes contemplated of using theinvention. The parts are parts by weight unless otherwise specified.

EXAMPLE 39

    ______________________________________                                        Tablets                                                                       A tablet composition is compounded from the following ingredients:            ______________________________________                                        Ethyl 2-(2-methyl-6-ethoxyoxalylpyrimidin-4-yl)                                                        0.010 parts                                          ethenylphenyl-4 oxamate                                                       Stearic acid             0.010 parts                                          Dextrose                 1.890 parts                                          TOTAL                    1.910 parts                                          ______________________________________                                    

The ingredients are admixed in conventional manner, and the mixture iscompressed into 1.91 g tablets, each of which is an oral dosage unitcomposition containing 10 mg of the active ingredient.

EXAMPLE 40

    ______________________________________                                        Ointment                                                                      An ointment composition is compounded from the following                      ingredients:                                                                  ______________________________________                                        Ethyl 2-(3-pyridazinyl)ethenylphenyl-4 oxamate                                                        2.000 parts                                           Fuming hydrochloric acid                                                                              0.011 parts                                           Sodium pyrosulfite      0.050 parts                                           Mixture (1:1) of cetyl alcohol and stearyl                                                            20.000 parts                                          alcohol                                                                       White vaseline          5.000 parts                                           Synthetic bergamot oil  0.075 parts                                           Distilled water q.s. ad 100.000 parts                                         ______________________________________                                    

The ingredients are uniformly blended in conventional manner into anointment, 100 g of which contain 2.0 g of the active ingredient.

EXAMPLE 41

    ______________________________________                                        Inhalation aerosol                                                            An aerosol composition is compounded from the following                       ______________________________________                                        ingredients:                                                                  Ethyl 2-(4-pyrimidinyl)ethenylphenyl-4 oxamate                                                         1.00 parts                                           Soybean lecithin         0.20 parts                                           Propellant gas mixture (Freon 11, 12 and 14) q.s.                                                      100.00 parts                                         ______________________________________                                    

The ingredients are compounded in conventional manner, and thecomposition is filled into aerosol containers with a metering valvewhich releases 0.5 to 2.0 mg of active ingredient per actuation of thevalve.

EXAMPLE 42

    ______________________________________                                        Hypodermic solution                                                           A solution is compounded from the following ingredients:                      ______________________________________                                        2-(2-Methyl-6-carboxycarbonylamino-pyrimidin-4-                                                        5.0 parts                                            yl)ethenylphenyl-4 oxamate diethanolamine salt                                Sodium pyrosulfite       1.0 parts                                            Sodium salt of EDTA      0.5 parts                                            Sodium chloride          8.5 parts                                            Double-distilled water q.s. ad                                                                         1000.0 parts                                         ______________________________________                                    

The individual ingredients are dissolved in a sufficient amount ofdouble-distilled water, the solution is diluted to the indicatedconcentration with additional double-distilled water, the resultingsolution is filtered until free from suspended particles, and thefiltrate is filled under aseptic conditions into 1 ml-ampules which aresubsequently sterilized and sealed. Each ampule contains 5 mg of theactive ingredient.

Any one of the other compounds embraced by formula I or a nontoxic,pharmceutically acceptable salt thereof can be substituted for theparticular active ingredient in the above formulation examples.Likewise, the amount of active ingredient in these illustrative examplescan be varied to achieve the dosage unit range set forth above, and theamounts and nature of the inert pharmaceutical carrier ingredient can bevaried to meet particular requirements.

While the present invention has been illustrated with the aid of certainspecific embodiments thereof, it will be readily apparent to otherskilled in the art that the invention is not limited to these particularembodiments and that various changes and modifications may be madewithout departing from the scope of the invention.

What is claimed is:
 1. A compound of the formula ##STR45## wherein R₁ ishydrogen or alkyl of 1 to 4 carbon atoms;R₂ is hydrogen, methyl,hydroxyl, alkoxy of 1 to 4 carbon atoms, di(alkyl of 1 to 2 carbonatoms) amino-(alkoxy of 1 to 4 carbon atoms) or halogen; R₃ is hydrogenor NHCOCOOR₁ ; A is ##STR46## R₄ is hydrogen, methyl, alkoxy of 1 to 4carbons atoms, hydroxyl, amino, alkanoyloxy of 1 to 2 carbon atoms,di(alkyl of 1 to 2 carbon atoms)-amino-(alkoxy of 1 to 4 carbon atoms)or acetamido; and R₅ is hydrogen, amino, alkoxy of 1 to 4 carbon atoms,halogen or NHCOCOOR₁ ;or, when R₁ is hydrogen, a nontoxic,pharmaceutically acceptable salt thereof.
 2. A compound of claim 1wherein R₄ is hydrogen or methyl.
 3. The compound of claim 2 which isethyl 2-(2-pyrazinyl)ethenylphenyl-4 oxamate.
 4. The compound of claim 2which is 2-(2-pyrazinyl)ethenylphenyl-4 oxamic acid sodium salt.
 5. Thecompound of claim 2 which is ethyl 2-(2-pyrazinyl)ethenylphenyl-3oxamate.
 6. The compound of claim 2 which is the ethanolamine salt of2-(2-pyrazinyl)ethenylphenyl-3 oxamic acid.
 7. The compound of claim 2which is ethyl 2-(3-ethylpyrazin-2-yl)ethenylphenyl-4 oxamate.
 8. Thecompound of claim 2 which is 2-(3-ethylpyrazin-2-yl)ethenylphenyl-4oxamic acid ethanolamine salt.
 9. The compound of claim 2 which isethoxyethyl 2-(2-pyrazinyl)ethenylphenyl-4 oxamate.
 10. The compound ofclaim 2 which is diethyl 2-(2-pyrazinyl)ethenylphenyl-2,4 dioxamate. 11.The compound of claim 2 which is 2-(2-pyrazinyl)ethenylphenyl-2 4dioxamic acid diethanolamine salt.
 12. A composition comprising aneffective antiallergic amount of a compound of claims 1 or 2 and anontoxic, pharmaceutically acceptable carrier.
 13. A compositioncomprising an effective antiinflammatory amount of a compound of claims1 or 2 and a nontoxic, pharmaceutically acceptable carrier.
 14. A methodof treating an allergic disorder in a mammal in need thereof, whichcomprises administering an effective amount of a compound of claims 1 or2 to said mammal.
 15. A method of treating an inflammatory disorder in amammal in need thereof, which comprises administering an effectiveamount of a compound of claims 1 or 2 to said mammal.